SIGNIFICANCE OF EXPRESSION OF MOLECULAR MARKERS IN DIAGNOSTICS OF PRECANCEROUS LESIONS AND TRANSFORMATIONS OF GASTRIC MUCOSA

DOI: https://doi.org/None

A.B. Denisova (1,2), A.B. Salmina (1), D.V. Cherdantsev (1), E.G. Grishchenko (1), P.S. Zhegalov (2) 1 -Krasnoyarsk State Medical University named after Prof. V.F. Voino–Yasenetsky, P. Zheleznyaka str., 1, Krasnoyarsk, 660022, Russian Federation; 2 -Krasnoyarsk Regional Hospital, P. Zheleznyaka str., 3a, Krasnoyarsk, 660022, Russian Federation

Introduction. Gastric cancer is a global problem for the health systems worldwide. Today it takes the fourth place in the world in the morbidity and the second place in the mortality structure. In Russian Federation, almost 70% of gastric cancer cases are diagnosed at III–IV stage of the pathological process that leads to unsatisfactory results of treatment and poor prognosis. This situation determines the need for early diagnostics of gastric cancer at the stage of precancerous conditions and transformations of gastric mucosa. The aim is given to studying carcinogenesis, particularly in patients with precancerous pathology. Aim of this review was an invertigation of molecular markers of gastric cancer and its expression in precancerous conditions. Methods. Overview of acticles dedicated to molecular markers of gastric cancer was done. Results. Such an approach is an important aspect not only in diagnostics but also in the management of oncological diseases because the most of identified molecules involved into the transformation are the targets for anticancer therapy. Conclusion. There is a wide spectrum of studies dedicated to molecular mechanisms of cancerous lesions. But at the same time, molecular markers expression in precancerous conditions and lesions requires further investigation.
Keywords: 
gastric cancer, molecular markers, intestinal metaplasia, apoptosis, growth factors signaling pathways

Список литературы: 
  1. Jemal A. Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global Cancer Statistics. Cancer J. Clin. 2011; 61 (2): 69–90.
  2. Pod red. Chissova V.I., Starinskogo V.V., Petrovoy G.V.. Zlokachestvennye novoobrazovaniya v Rossii v 2010 g. M.: FGBU «MNIOI im. P.A. Gercena», 2012; 260. [Chissov V.I., Starinskiy V.V., Petrova G.V., editors. Malignancies in Russia in 2010. M.: «Federal Government Budget Oraganisation P.A. Gertsen Moscow Research Oncological Institute», 2012; 260 (in Russian)]
  3. Volkova N.N. Faktory riska razvitiya hronicheskogo atroficheskogo gastrita (literaturnyy obzor). RMZh. 2013; 31: 1617–21. [Volkova N. N. Risk factors of chronic atrophic gastritis development (review). Rossiyskiy medicinskiy zhurnal. 2013; 31: 1617–21 (in Russian)]
  4. Dinis-Ribeiro M., Areia M, de Vries A.C., Marcos-Pinto R., Monteiro-Soares M., O’Connor A., Pereira C., Pimentel-Nunes P., Correia R., Ensari A., Dumonceau J.M., Machado J.C., Macedo G., Malfertheiner P., Matysiak-Budnik T., Megraud F., Miki K., O’Morain C., Peek R.M.,Ponchon T., Ristimaki A., Rembacken B., Carneiro F., Kuipers E.J., European Society of Gastrointestinal Endoscopy; European Helicobacter Study Group; European Society of Pathology; Sociedade Portuguesa de Endoscopia Digestiva.. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology(ESP), and the Sociedade Portuguesa de EndoscopiaDigestiva (SPED). Endoscopy. 2012; 44: 74–94.
  5. Hamilton S.R., Aaltonen L. A. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon, IARC Press. 2000; 314.
  6. Correa P., Piazuelo M.B. The gastric precancerous cascade. J Dig Dis. 2012; 13 (1): 2–9.
  7. Meng, X Zhou Y., Dang T., Tian X.Y., Kong J. Magnifying chromoendoscopy combined with immunohistochemical staining for early diagnosis of gastric cancer. World J. Gastroenterol. 2013; 19 (3): 404–10.
  8. Lam K.W.K., Lo S.C.L. Discovery of diagnostic serum biomarkers of gastric cancer using proteomics. Proteomics Clin. Appl. 2008; 2: 219–28.
  9. Yong H.Y., Moon A. Roles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells. Arch. Pharm. Res. 2007; 30: 75–81.
  10. Tanner S.M., Li Z., Perko J.D., Oner C., Cetin M., Altay C., Yurtsever Z., David K.L., Faivre L., Ismail E.A., Gräsbeck R., de la Chapelle A. Hereditary juvenile cobalamin deficiency caused by mutations in the intrinsic factor gene. Proc. Natl. Acad. Sci. USA. 2005; 102: 4130–3.
  11. Wu W., Juan W.C., Liang C.R., Yeoh K.G., So J., Chung M.C. S100A9, GIF and AAT as potential combinatorial biomarkers in gastric cancer diagnosis and prognosis. Proteomics Clin. Appl. 2012; 6: 152–62.
  12. Gravalos C., Jimeno A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol. 2008; 19: 1523–9.
  13. Janjigian Y.Y. Tang L.H., Coit D.G., Kelsen D.P., Francone T.D., Weiser M.R., Jhanwar S.C., Shah M.A. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev. 2011; 20: 1021–7.
  14. Seo H.M., Chang Y.S., Joo S.H., Kim Y.W., Park Y.K., Hong S.W., Lee S.H. Clinicopathologic Characteristics and Outcomes of Gastric Cancers With the MSI-H Phenotype. J. Surg. Oncol. 2009; 99: 143–7.
  15. Beroukhim R. Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., Mc Henry K.T., Pinchback R.M., Ligon A.H., Cho Y.J., Haery L., Greulich H., Reich M., Winckler W., Lawrence M.S., Weir B.A., Tanaka K.E., Chiang D.Y., Bass A.J., Loo A., Hoffman C., Prensner J., Liefeld T., Gao Q., Yecies D., Signoretti S., Maher E., Kaye F.J., Sasaki H., Tepper J.E., Fletcher J.A., Tabernero J., Baselga J., Tsao M.S., Demichelis F., Rubin M.A., Janne P.A., Daly M.J., Nucera C., Levine R.L., Ebert B.L., Gabriel S., Rustgi A.K., Antonescu C.R., Ladanyi M., Letai A., Garraway L.A., Loda M., Beer D.G., True L.D., Okamoto A., Pomeroy S.L., Singer S., Golub T.R., Lander E.S., Getz G., Sellers W.R., Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463: 899–905.
  16. Dong C.X. Deng D.J., Pan K.F., Zhang L., Zhang Y., Zhou J., You W.C. Promoter methylation of p16 associated with Helicobacter pylori infection in precancerous gastric lesions: A population-based study. Int. J. Cancer. 2010; 124: 434–9.
  17. Babashah S., Soleimani M. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. EurJ Cancer. 2011; 47: 1127–37.
  18. Carthew R.W., Sontheimer E.J. Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009; 136: 642–55.
  19. Wang F., Sun G.P., Zou Y.F., Hao J.Q., Zhong F., Ren W.J. MicroRNAs as promising biomarkers for gastric cancer. Cancer Biomarkers. 2012; 11: 259–67.
  20. Li X., Zhang Y., Zhang Y., Ding J., Wu K., Fan D. Survival prediction of gastric cancer by a seven-microRNA signature. Gut. 2010; 59: 579–85.
  21. Mitrut P., Nescu A., Streba L.A.M. The endoscopic and morphological forms of early gastric cancer. Romanian J. of Morphology and Embryology. 2007; 48 (4): 373–9.
  22. Anagnostopoulos G.K., Stefanou D., Arkoumani E., Chalkley L., Karagiannis J., Paraskeva K., Mathou N., Dellaporta E., Tsianos E., Agnantis N.J. Expression of BAX protein in gastric carcinomas. A clinicopathological and immunohistochemical study. Acta Gastroenterol. Belg. 2007; 70: 285–9.
  23. Lee G.H., Joo Y.E., Koh Y.S., Chung I.J., Park Y.K., Lee J.H., Kim H.S., Choi S.K., Rew J.S., Park C.S., Kim S.J. Expression of survivin in gastric cancer and its relationship with tumour angiogenesis. Eur. J. Gastroenterol. Hepatol. 2006; 18: 957–63.
  24. Lee H.K., Lee H.S., Yang H.K., Kim W.H., Lee K.U., Choe K.J., Kim J.P. Prognostic significance of BCL-2 and TP53 expression in gastric cancer. Int J Colorectal Dis. 2003; 18: 518–25.
  25. Xu Z., Zhang Y., Jiang J., Yang Y., Shi R., Hao B., Zhang Z., Huang Z., Kim J.W., Zhang G. Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells. BMC Cancer. 2010; 10 (161).
  26. Yu G., Wang J., Chen Y., Wang X., Pan J., Li G., Jia Z., Li Q., Yao J.C., Xie K. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res. 2009; 15: 1821–9.
  27. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase–akt pathway in human cancer. Nat Rev Cancer. 2002; 2 (7): 489–501.
  28. Yap T.A., Garrett M.D., Walton M.I., Raynaud F., de Bono J.S., Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 2008; 4: 393–412.
  29. Turcotte S., Chan D.A., Sutphin P.D. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell. 2008; 14: 90–102.
  30. Fuhler G.M., Tyl M.R., Olthof S.G. Lyndsay Drayer A., Blom N., Vellenga E.. Distinct roles of the mTOR components Rictor and Raptor in MO7e megakaryocytic cells. Eur. J. Haematol. 2009; 83: 235–45.
  31. Yuan R.R., Kay A., Berg W.J. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J HematolOncol. 2009; 2: 45.
  32. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004; 4: 335–48.
  33. Liu Q., Thoreen C., Wang J., Sabatini D., Gray N.S. mTOR mediated anti-cancer drug discovery. Drug Discov Today TherStrateg. 2009; 6: 47–55.
  34. Li M., Sun H., Song L., Gao X., Chang W., Qin X. Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma. Oncology Letters. 2012; 4: 1213–8.
  35. Wong H., Yau T. Molecular targeted therapies in advanced gastric cancer: does tumor histology matter? Therap Adv Gastroenterol. 2013; 6 (1): 15–31.
  36. Xie X., Tang B., Zhou J., Gao Q., Zhang P. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncology Reports. 2013; 30 (2): 773–82.
  37. Manning B.D., Cantley L.C. AKT/PKB signaling: Navigating downstream. Cell. 2007; 129: 1261–74.
  38. Liu J.F., Zhou X.K., Chen J.H., Yi G., Chen H.G., Ba M.C., Lin S.Q., Qi Y.C. Up-regulation of PIK3CA promotes metastasis in gastric carcinoma. WorldJGastroenterol. 2010; 16 (39): 4986–91.
  39. Lieto E., Ferraraccio F., Orditura M., Castellano P., Mura A.L., Pinto M., Zamboli A., De Vita F., Galizia G. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 2008; 15: 69–79.
  40. Hwang J., Lee J.H., Park M.R., Kim D.E., Bae W.K., Shim H.J., Cho S.H., Chung I.J. Blockade of VEGFR-1 and VEGFR-2 Enhances Paclitaxel Sensitivity in Gastric Cancer Cells. Yonsei Med J. 2013; 54 (2): 374–80.
  41. Koo B.H., Longpré J.M., Somerville R.P. Regulation of ADAMTS9 secretion and enzymatic activity by its propeptide. J. Biol. Chem. 2007; 282 (22): 16146–54.
  42. Lo P.H., Leung A.C., Kwok C.Y. Identification of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9. Oncogene. 2007; 26 (1): 148–57.
  43. Koo B., Coe D.M., Dixon L.J., Somerville R.P., Nelson C.M., Wang L.W., Young M.E., Lindner D.J., Apte S.S. ADAMTS9 Is a Cell-Autonomously Acting, Anti-Angiogenic Metalloprotease Expressed by Microvascular Endothelial Cells. The Am. J. of Pathology. 2010; 176 (3): 1494–504.
  44. Du W., Wang S., Zhou Q., Li X., Chu J., Chang Z., Tao Q., Ng E.K., Fang J., Sung J.J., Yu J. ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer. Oncogene. 2012; 32 (28): 3319–28.
  45. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev. Mol. Cell. Biol. 2011; 12: 21–35.
  46. Pietrantonio F., De Braud F., Da Prat V., Perrone F., Pierotti M.A., Gariboldi M., Fanetti G., Biondani P., Pellegrinelli A., Bossi I., Di Bartolomeo M. A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res. 2013; 33 (4): 1257–66.
  47. Tian W.-Y., Chen W.-C., Li R., Liu L. Markers CD40, VEGF, AKT, PI3K, and S100 Correlate with Tumor Stage in Gastric Cancer. Onkologie. 2013; 36: 26–31.
  48. Guertin D.A., Sabatini D.M.: Defining the role of mTOR in cancer. Cancer Cell. 2007; 12: 9–22.
  49. Koo B.H., Longpré J.M., Somerville R.P. Cell-surface processing of pro-ADAMTS9 by furin. J. Biol. Chem. 2006; 281 (18): 12485–94.